Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11033MR)

This product GTTS-WQ11033MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11033MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6148MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ359MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ14720MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ564MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ2185MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ9473MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ4328MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ7918MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW